{"protocolSection": {"identificationModule": {"nctId": "NCT00643851", "orgStudyIdInfo": {"id": "MB102-021"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets", "officialTitle": "A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Metformin as Initial Therapy as Compared With Dapagliflozin Monotherapy and Metformin Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control"}, "statusModule": {"statusVerifiedDate": "2023-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-06"}, "primaryCompletionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-03-20", "studyFirstSubmitQcDate": "2008-03-20", "studyFirstPostDateStruct": {"date": "2008-03-26", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-09-30", "resultsFirstSubmitQcDate": "2017-01-05", "resultsFirstPostDateStruct": {"date": "2017-02-23", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-01-27", "lastUpdatePostDateStruct": {"date": "2023-01-30", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}, "collaborators": [{"name": "Bristol-Myers Squibb", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this clinical research study is to learn if initiating treatment with BMS-51248 (Dapagliflozin) in combination with metformin XR can improve diabetes control in patients with Type 2 Diabetes who do not receive any pharmacological treatment for diabetes, when compared to initial treatment with monotherapy dapagliflozin or metformin XR. The safety of this treatment will also be studied"}, "conditionsModule": {"conditions": ["Type 2 Diabetes"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 994, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Arm 1", "type": "EXPERIMENTAL", "description": "Dapagliflozin (5 mg) + Metformin XR (up to 2000 mg)", "interventionNames": ["Drug: Dapagliflozin", "Drug: Metformin XR"]}, {"label": "Arm 2", "type": "EXPERIMENTAL", "description": "Dapagliflozin (5 mg)", "interventionNames": ["Drug: Dapagliflozin"]}, {"label": "Arm 3", "type": "ACTIVE_COMPARATOR", "description": "Metformin XR (500 mg up to 2000 mg)", "interventionNames": ["Drug: Metformin XR"]}], "interventions": [{"type": "DRUG", "name": "Dapagliflozin", "description": "Tablets, Oral, Once daily, 24 weeks", "armGroupLabels": ["Arm 1", "Arm 2"], "otherNames": ["BMS-512148"]}, {"type": "DRUG", "name": "Metformin XR", "description": "Tablets, Oral, Once daily, 24 weeks", "armGroupLabels": ["Arm 1", "Arm 3"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])", "description": "HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 4, 8, 12, 16, 20, and 24 in the double- blind period.", "timeFrame": "From Baseline to Week 24"}], "secondaryOutcomes": [{"measure": "Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Last Observation Carried Forward [LOCF])", "description": "Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Fasting plasma glucose was measured as milligrams per deciliter(mg/dL) by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 in the double-blind period.", "timeFrame": "From Baseline to Week 24"}, {"measure": "Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])", "description": "Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Percent adjusted for baseline HbA1c. Therapeutic glycemic response is defined as HbA1c \\<7.0%. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin. Mean and standard error for percentage of participants estimated by modified logistic regression model.", "timeFrame": "From Baseline to Week 24"}, {"measure": "Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) in Subjects With Baseline HbA1c \u2265 9% at Week 24 (Last Observation Carried Forward [LOCF])", "description": "HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 4, 8, 12, 16, 20, and 24 in the double-blind period.", "timeFrame": "From Baseline to Week 24"}, {"measure": "Adjusted Mean Change From Baseline in Total Body Weight (kg) at Week 24 (Last Observation Carried Forward [LOCF])", "description": "Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Adjusted mean change from baseline in total body weight at Week 24 (or the last postbaseline measurement prior to Week 24 if no Week 24 assessment was available was determined. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of the double-blind period.", "timeFrame": "From Baseline to Week 24"}, {"measure": "Adjusted Mean Change From Baseline in Total Body Weight (kg) in Subjects With Baseline Body Mass Index (BMI) \u2265 27 kg/m^2 at Week 24 (Last Observation Carried Forward [LOCF])", "description": "Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Adjusted mean change from baseline in total body weight at Week 24 (or the last postbaseline measurement prior to Week 24 if no Week 24 assessment was available was determined. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of the double-blind period.", "timeFrame": "From Baseline to Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Males \\& females, 18-77 years old inclusive, with type 2 diabetes and with inadequate glycemic control\n* Drug naive or treated with anti-diabetic medication for \\< 24 weeks since original diagnosis\n* C-peptide \u2265 1.0 ng/mL\n* Body Mass Index \u2264 45.0 kg/m\n* Serum creatinine \\< 1.50 mg/dL for men or \\< 1.40 mg/dL for women\n\nExclusion Criteria:\n\n* AST and/or ALT \\>3.0 times the upper limit of normal (ULN)\n* Serum total bilirubin \\> 2.0 mg/dL\n* Creatine kinase \\> 3X the upper limit of normal (ULN)\n* Symptoms of severely uncontrolled diabetes\n* Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric or rheumatic diseases", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "77 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bristol-Myers Squibb", "affiliation": "Bristol-Myers Squibb", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Greystone Medical Research, Llc", "city": "Birmingham", "state": "Alabama", "zip": "35242", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Winston Technology Research, Llc", "city": "Haleyville", "state": "Alabama", "zip": "35565", "country": "United States", "geoPoint": {"lat": 34.22649, "lon": -87.62141}}, {"facility": "Clinical Research Advantage, Inc.", "city": "Tempe", "state": "Arizona", "zip": "85282", "country": "United States", "geoPoint": {"lat": 33.41477, "lon": -111.90931}}, {"facility": "John Muir Physician Network Clinical Research Center", "city": "Concord", "state": "California", "zip": "94520", "country": "United States", "geoPoint": {"lat": 37.97798, "lon": -122.03107}}, {"facility": "Southland Clinical Research Center, Inc.", "city": "Fountain Valley", "state": "California", "zip": "92708", "country": "United States", "geoPoint": {"lat": 33.70918, "lon": -117.95367}}, {"facility": "Valley Research", "city": "Fresno", "state": "California", "zip": "93720", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "Central Florida Clinical Trials, Inc.", "city": "Altamonte Springs", "state": "Florida", "zip": "32701", "country": "United States", "geoPoint": {"lat": 28.66111, "lon": -81.36562}}, {"facility": "Clinical Therapeutics Corporation", "city": "Coral Gables", "state": "Florida", "zip": "33134", "country": "United States", "geoPoint": {"lat": 25.72149, "lon": -80.26838}}, {"facility": "Florida Research Network, Llc", "city": "Gainesville", "state": "Florida", "zip": "32605", "country": "United States", "geoPoint": {"lat": 29.65163, "lon": -82.32483}}, {"facility": "Fpa Clinical Research", "city": "Kissimmee", "state": "Florida", "zip": "34741", "country": "United States", "geoPoint": {"lat": 28.30468, "lon": -81.41667}}, {"facility": "Nextphase Clinical Trials, Inc.", "city": "Miami", "state": "Florida", "zip": "33145", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Middle Georgia Drug Study Center, Llc", "city": "Perry", "state": "Georgia", "zip": "31069", "country": "United States", "geoPoint": {"lat": 32.45821, "lon": -83.73157}}, {"facility": "Cedar Crosse Research Center", "city": "Chicago", "state": "Illinois", "zip": "60607", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Deerbrook Medical Associates", "city": "Vernon Hills", "state": "Illinois", "zip": "60061", "country": "United States", "geoPoint": {"lat": 42.21947, "lon": -87.97952}}, {"facility": "Jackson Clinic", "city": "Rolling Fork", "state": "Mississippi", "zip": "39159", "country": "United States", "geoPoint": {"lat": 32.90652, "lon": -90.87816}}, {"facility": "Mercy Medical Group/Dba Woodlake Research", "city": "Chesterfield", "state": "Missouri", "zip": "63017", "country": "United States", "geoPoint": {"lat": 38.66311, "lon": -90.57707}}, {"facility": "Hudson Valley Clinical Research Center", "city": "Kingston", "state": "New York", "zip": "12401", "country": "United States", "geoPoint": {"lat": 41.92704, "lon": -73.99736}}, {"facility": "Metrolina Medical Research", "city": "Charlotte", "state": "North Carolina", "zip": "28209", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Crescent Medical Research", "city": "Salisbury", "state": "North Carolina", "zip": "28144", "country": "United States", "geoPoint": {"lat": 35.67097, "lon": -80.47423}}, {"facility": "Community Health Care, Inc.", "city": "Canal Fulton", "state": "Ohio", "zip": "44614", "country": "United States", "geoPoint": {"lat": 40.88978, "lon": -81.59762}}, {"facility": "Wells Institute For Health Awareness", "city": "Kettering", "state": "Ohio", "zip": "45429", "country": "United States", "geoPoint": {"lat": 39.6895, "lon": -84.16883}}, {"facility": "Newark Physician Associates", "city": "Newark", "state": "Ohio", "zip": "43055", "country": "United States", "geoPoint": {"lat": 40.05812, "lon": -82.40126}}, {"facility": "Physician Research, Inc.", "city": "Zanesville", "state": "Ohio", "zip": "43701", "country": "United States", "geoPoint": {"lat": 39.94035, "lon": -82.01319}}, {"facility": "Gilbert Medical Research, Llc", "city": "Bethany", "state": "Oklahoma", "zip": "73008", "country": "United States", "geoPoint": {"lat": 35.51867, "lon": -97.63226}}, {"facility": "Integris Family Care South Penn", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73159", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Integris Family Care Yukon", "city": "Yukon", "state": "Oklahoma", "zip": "73099", "country": "United States", "geoPoint": {"lat": 35.50672, "lon": -97.76254}}, {"facility": "Willamette Valley Clinical Studies", "city": "Eugene", "state": "Oregon", "zip": "97404", "country": "United States", "geoPoint": {"lat": 44.05207, "lon": -123.08675}}, {"facility": "Commonwealth Primary Care, Pc / Fleetwood Clinical Research", "city": "Fleetwood", "state": "Pennsylvania", "zip": "19522", "country": "United States", "geoPoint": {"lat": 40.45398, "lon": -75.81798}}, {"facility": "Biomedical Research Associates, Llc", "city": "Shippensburg", "state": "Pennsylvania", "zip": "17257", "country": "United States", "geoPoint": {"lat": 40.05065, "lon": -77.52026}}, {"facility": "Safe Harbor Clinical Research", "city": "East Providence", "state": "Rhode Island", "zip": "02914", "country": "United States", "geoPoint": {"lat": 41.81371, "lon": -71.37005}}, {"facility": "Southeastern Research Associates, Inc.", "city": "Greenville", "state": "South Carolina", "zip": "29605", "country": "United States", "geoPoint": {"lat": 34.85262, "lon": -82.39401}}, {"facility": "Spartanburg Medical Research", "city": "Spartanburg", "state": "South Carolina", "zip": "29303", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Middle Tennessee Clinical Research", "city": "Fayetteville", "state": "Tennessee", "zip": "37334", "country": "United States", "geoPoint": {"lat": 35.15203, "lon": -86.57055}}, {"facility": "Holston Medical Group", "city": "Kingsport", "state": "Tennessee", "zip": "37660", "country": "United States", "geoPoint": {"lat": 36.54843, "lon": -82.56182}}, {"facility": "Endocrine Associates", "city": "Houston", "state": "Texas", "zip": "77004", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Village Family Practice", "city": "Houston", "state": "Texas", "zip": "77024", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Non-Invasive Cardiovascular, Pa", "city": "Houston", "state": "Texas", "zip": "77074", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Excel Clinical Research, Llc", "city": "Houston", "state": "Texas", "zip": "77081", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Texas Center For Drug Development", "city": "Houston", "state": "Texas", "zip": "77081", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Inst. Of Clin. Research At The Diabetes Cntr. Of The Sw", "city": "Midland", "state": "Texas", "zip": "79705", "country": "United States", "geoPoint": {"lat": 31.99735, "lon": -102.07791}}, {"facility": "Hill Country Medical Associates", "city": "New Braunfels", "state": "Texas", "zip": "78130", "country": "United States", "geoPoint": {"lat": 29.703, "lon": -98.12445}}, {"facility": "Southwest Clinical Research Center, Llc", "city": "Pearland", "state": "Texas", "zip": "77584", "country": "United States", "geoPoint": {"lat": 29.56357, "lon": -95.28605}}, {"facility": "Covenant Clinical Research, Pa", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "S.A.M. Clinical Research Center", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Local Institution", "city": "Guri-Si", "state": "Gyeonggi-Do", "zip": "471-701", "country": "Korea, Republic of", "geoPoint": {"lat": 37.5986, "lon": 127.1394}}, {"facility": "Local Institution", "city": "Seoul", "state": "Nowon-Gu", "zip": "471-701", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Local Institution", "city": "Bucheon", "zip": "420-717", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "Local Institution", "city": "Incheon", "zip": "105-760", "country": "Korea, Republic of", "geoPoint": {"lat": 37.45646, "lon": 126.70515}}, {"facility": "Local Institution", "city": "Incheon", "zip": "400-711", "country": "Korea, Republic of", "geoPoint": {"lat": 37.45646, "lon": 126.70515}}, {"facility": "Local Institution", "city": "Seoul", "zip": "137-040", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Local Institution", "city": "Sungnam-Si, Gyeonggi-Do", "zip": "463-070", "country": "Korea, Republic of"}, {"facility": "Local Institution", "city": "Ciudad De Mexico", "state": "Distrito Federal", "zip": "14000", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Local Institution", "city": "Pachuca", "state": "Hidelgo", "zip": "42090", "country": "Mexico", "geoPoint": {"lat": 20.11697, "lon": -98.73329}}, {"facility": "Local Institution", "city": "Guadalajara", "state": "Jalisco", "zip": "44100", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Local Institution", "city": "Guadalajara", "state": "Jalisco", "zip": "44650", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Local Institution", "city": "Guadalajara", "state": "Jalisco", "zip": "44670", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Local Institution", "city": "Morelia", "state": "Michioacan", "zip": "58070", "country": "Mexico", "geoPoint": {"lat": 19.70078, "lon": -101.18443}}, {"facility": "Local Institution", "city": "Monterrey, Nl", "state": "Nuevo Leon", "zip": "64400", "country": "Mexico"}, {"facility": "Local Institution", "city": "Monterrey", "state": "Nuevo Leon", "zip": "64000", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Local Institution", "city": "Tampico", "state": "Tamaulipas", "zip": "89000", "country": "Mexico", "geoPoint": {"lat": 22.26695, "lon": -97.86815}}, {"facility": "Local Institution", "city": "Merida", "state": "Yucatan", "zip": "97070", "country": "Mexico", "geoPoint": {"lat": 20.97537, "lon": -89.61696}}, {"facility": "Local Institution", "city": "Aguascalientes", "zip": "20127", "country": "Mexico", "geoPoint": {"lat": 21.88234, "lon": -102.28259}}, {"facility": "Local Institution", "city": "Durango", "zip": "34000", "country": "Mexico", "geoPoint": {"lat": 24.02032, "lon": -104.65756}}, {"facility": "Local Institution", "city": "Veracruz", "zip": "91910", "country": "Mexico", "geoPoint": {"lat": 19.18095, "lon": -96.1429}}, {"facility": "Local Institution", "city": "Cebu City", "zip": "6000", "country": "Philippines", "geoPoint": {"lat": 10.31672, "lon": 123.89071}}, {"facility": "Local Institution", "city": "Jaro Iloilo City", "zip": "5000", "country": "Philippines"}, {"facility": "Local Institution", "city": "Las Pinas City", "zip": "1740", "country": "Philippines"}, {"facility": "Local Institution", "city": "Marikina City", "zip": "1800", "country": "Philippines", "geoPoint": {"lat": 14.6481, "lon": 121.1133}}, {"facility": "Local Institution", "city": "Pasig City", "zip": "1600", "country": "Philippines", "geoPoint": {"lat": 14.58691, "lon": 121.0614}}, {"facility": "Local Institution", "city": "Quezon City", "zip": "1100", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "Local Institution", "city": "Ponce", "zip": "00716", "country": "Puerto Rico", "geoPoint": {"lat": 18.01108, "lon": -66.61406}}, {"facility": "Local Institution", "city": "Ponce", "zip": "00717", "country": "Puerto Rico", "geoPoint": {"lat": 18.01108, "lon": -66.61406}}, {"facility": "Local Institution", "city": "San Juan", "zip": "00920", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"facility": "Local Institution", "city": "San Juan", "zip": "00926", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"facility": "Local Institution", "city": "Villa Fontana", "zip": "00983", "country": "Puerto Rico", "geoPoint": {"lat": 18.40439, "lon": -65.9735}}, {"facility": "Local Institution", "city": "Arkhangelsk", "zip": "163045", "country": "Russian Federation", "geoPoint": {"lat": 64.5401, "lon": 40.5433}}, {"facility": "Local Institution", "city": "Dzerzhinskiy", "zip": "140091", "country": "Russian Federation", "geoPoint": {"lat": 55.62945, "lon": 37.85654}}, {"facility": "Local Institution", "city": "Kemerovo", "zip": "650066", "country": "Russian Federation", "geoPoint": {"lat": 55.33333, "lon": 86.08333}}, {"facility": "Local Institution", "city": "Moscov", "zip": "119048", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Local Institution", "city": "Moscow", "zip": "125299", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Local Institution", "city": "Nizhniy Novgorod", "zip": "603018", "country": "Russian Federation", "geoPoint": {"lat": 56.32867, "lon": 44.00205}}, {"facility": "Local Institution", "city": "Novosibirsk", "zip": "630091", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "Local Institution", "city": "Novosibirsk", "zip": "630117", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "Local Institution", "city": "Saint-Petersburg", "zip": "190068", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Local Institution", "city": "Saratov", "zip": "410028", "country": "Russian Federation", "geoPoint": {"lat": 51.54056, "lon": 46.00861}}, {"facility": "Local Institution", "city": "St. Petersburg", "zip": "191015", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Local Institution", "city": "Volgograd", "zip": "400001", "country": "Russian Federation", "geoPoint": {"lat": 48.71939, "lon": 44.50183}}, {"facility": "Local Institution", "city": "Voronezh", "zip": "394018", "country": "Russian Federation", "geoPoint": {"lat": 51.67204, "lon": 39.1843}}, {"facility": "Local Institution", "city": "Yaroslav", "zip": "150003", "country": "Russian Federation"}, {"facility": "Local Institution", "city": "Dnepropetrovsk", "zip": "49023", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "Local Institution", "city": "Donetsk", "zip": "83003", "country": "Ukraine", "geoPoint": {"lat": 48.023, "lon": 37.80224}}, {"facility": "Local Institution", "city": "Kiev", "zip": "04050", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Local Institution", "city": "Kiev", "zip": "4114", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Local Institution", "city": "Lviv", "zip": "79010", "country": "Ukraine", "geoPoint": {"lat": 49.83826, "lon": 24.02324}}, {"facility": "Local Institution", "city": "Odessa", "zip": "65009", "country": "Ukraine", "geoPoint": {"lat": 46.47747, "lon": 30.73262}}, {"facility": "Local Institution", "city": "Odessa", "zip": "65039", "country": "Ukraine", "geoPoint": {"lat": 46.47747, "lon": 30.73262}}, {"facility": "Local Institution", "city": "Odessa", "zip": "65114", "country": "Ukraine", "geoPoint": {"lat": 46.47747, "lon": 30.73262}}, {"facility": "Local Institution", "city": "Vinnytsya", "zip": "21010", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}, {"facility": "Local Institution", "city": "Zhytomyr", "zip": "10003", "country": "Ukraine", "geoPoint": {"lat": 50.26487, "lon": 28.67669}}]}, "referencesModule": {"references": [{"pmid": "22413962", "type": "RESULT", "citation": "Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012 May;66(5):446-56. doi: 10.1111/j.1742-1241.2012.02911.x. Epub 2012 Mar 13."}, {"pmid": "26894924", "type": "DERIVED", "citation": "Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L. The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol. 2016 Jun;29(3):391-400. doi: 10.1007/s40620-016-0261-1. Epub 2016 Feb 19."}], "seeAlsoLinks": [{"label": "Publication", "url": "http://onlinelibrary.wiley.com/doi/10.1111/j.1742-1241.2012.02911.x/epdf"}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Of 994 participants enrolled, 632 completed a qualification period. Of these 632 participants, 603 were randomized. Of these 603 randomized, 598 received at least one dose of study medication treatment. Of these 598 randomized, 518 completed double-blind treatment period.", "groups": [{"id": "FG000", "title": "Dapagliflozin 5 mg + Metformin XR", "description": "Dapagliflozin tablets, oral, once daily for 24 weeks plus metfomin XR tablets (up to 2000mg), oral, once daily for 24 weeks"}, {"id": "FG001", "title": "Dapagliflozin 5 mg", "description": "Dapagliflozin tablets, oral, once daily for 24 weeks"}, {"id": "FG002", "title": "Metformin XR", "description": "Metfomin XR tablets (500mg up to 2000mg), oral, once daily for 24 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "194"}, {"groupId": "FG001", "numSubjects": "203"}, {"groupId": "FG002", "numSubjects": "201"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "177"}, {"groupId": "FG001", "numSubjects": "170"}, {"groupId": "FG002", "numSubjects": "171"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "33"}, {"groupId": "FG002", "numSubjects": "30"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "9"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "9"}]}, {"type": "Non-compl., not met criteria, etc.", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "6"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All randomized participants who received at least 1 dose of study medication", "groups": [{"id": "BG000", "title": "Dapagliflozin 5 mg + Metformin XR", "description": "Dapagliflozin tablets, oral, once daily for 24 weeks plus metfomin XR tablets (up to 2000mg), oral, once daily for 24 weeks"}, {"id": "BG001", "title": "Dapagliflozin 5 mg", "description": "Dapagliflozin tablets, oral, once daily for 24 weeks"}, {"id": "BG002", "title": "Metformin XR", "description": "Metfomin XR tablets (500mg up to 2000mg), oral, once daily for 24 weeks"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "194"}, {"groupId": "BG001", "value": "203"}, {"groupId": "BG002", "value": "201"}, {"groupId": "BG003", "value": "598"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "51.7", "spread": "9.31"}, {"groupId": "BG001", "value": "52.3", "spread": "10.20"}, {"groupId": "BG002", "value": "51.8", "spread": "9.80"}, {"groupId": "BG003", "value": "52.0", "spread": "9.77"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Younger than 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "177"}, {"groupId": "BG001", "value": "183"}, {"groupId": "BG002", "value": "184"}, {"groupId": "BG003", "value": "544"}]}]}, {"title": "65 to younger than 75 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "16"}, {"groupId": "BG003", "value": "50"}]}]}, {"title": "75 years and older", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "4"}]}]}]}, {"title": "Sex/Gender, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Male", "categories": [{"measurements": [{"groupId": "BG000", "value": "78"}, {"groupId": "BG001", "value": "92"}, {"groupId": "BG002", "value": "95"}, {"groupId": "BG003", "value": "265"}]}]}, {"title": "Female", "categories": [{"measurements": [{"groupId": "BG000", "value": "116"}, {"groupId": "BG001", "value": "111"}, {"groupId": "BG002", "value": "106"}, {"groupId": "BG003", "value": "333"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "153"}, {"groupId": "BG001", "value": "166"}, {"groupId": "BG002", "value": "158"}, {"groupId": "BG003", "value": "477"}]}]}, {"title": "Black/African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "18"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "33"}, {"groupId": "BG002", "value": "35"}, {"groupId": "BG003", "value": "100"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "3"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])", "description": "HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 4, 8, 12, 16, 20, and 24 in the double- blind period.", "populationDescription": "All randomized participants who received study medication and had nonmissing values at baseline and Week 24 (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "% of hemoglobin", "timeFrame": "From Baseline to Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin 5 mg + Metformin XR", "description": "Dapagliflozin tablets, oral, once daily for 24 weeks plus metfomin XR tablets (up to 2000mg), oral, once daily for 24 weeks"}, {"id": "OG001", "title": "Dapagliflozin 5 mg", "description": "Dapagliflozin tablets, oral, once daily for 24 weeks"}, {"id": "OG002", "title": "Metformin XR", "description": "Metfomin XR tablets (500mg up to 2000mg), oral, once daily for 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "185"}, {"groupId": "OG001", "value": "196"}, {"groupId": "OG002", "value": "195"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.05", "spread": "0.0892"}, {"groupId": "OG001", "value": "-1.19", "spread": "0.0866"}, {"groupId": "OG002", "value": "-1.35", "spread": "0.0868"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "pValueComment": "Primary endpoint was tested at alpha=0.05; significance was claimed only if DAPA 5MG + MET was superior to both controls.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.86", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.11", "ciUpperLimit": "-0.62", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1243"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "pValueComment": "Primary endpoint was tested at alpha=0.05; significance was claimed only if DAPA 5MG + MET is superior to both controls.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.70", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.94", "ciUpperLimit": "-0.45", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1245"}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Last Observation Carried Forward [LOCF])", "description": "Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Fasting plasma glucose was measured as milligrams per deciliter(mg/dL) by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 in the double-blind period.", "populationDescription": "All randomized participants who received study medication and had nonmissing FPG values at baseline and Week 24 (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "From Baseline to Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin 5 mg + Metformin XR", "description": "Dapagliflozin tablets, oral, once daily for 24 weeks plus metfomin XR tablets (up to 2000mg), oral, once daily for 24 weeks"}, {"id": "OG001", "title": "Dapagliflozin 5 mg", "description": "Dapagliflozin tablets, oral, once daily for 24 weeks"}, {"id": "OG002", "title": "Metformin XR", "description": "Metfomin XR tablets (500mg up to 2000mg), oral, once daily for 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "192"}, {"groupId": "OG001", "value": "203"}, {"groupId": "OG002", "value": "200"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-61.0", "spread": "2.783"}, {"groupId": "OG001", "value": "-42.0", "spread": "2.708"}, {"groupId": "OG002", "value": "-33.6", "spread": "2.728"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "pValueComment": "Secondary endpoints were tested following a sequential testing procedure at alpha=0.05. Significance was claimed only if DAPA 5MG + MET is superior to both controls.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-19.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-26.7", "ciUpperLimit": "-11.4", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.883"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "pValueComment": "Secondary endpoints were tested following a sequential testing procedure at alpha=0.05. Significance was claimed only if DAPA 5MG + MET is superior to both controls.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-27.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-35.1", "ciUpperLimit": "-19.8", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.897"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])", "description": "Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Percent adjusted for baseline HbA1c. Therapeutic glycemic response is defined as HbA1c \\<7.0%. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin. Mean and standard error for percentage of participants estimated by modified logistic regression model.", "populationDescription": "All randomized participants who received study medication and had nonmissing values at baseline and Week 24 (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of participants", "timeFrame": "From Baseline to Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin 5 mg + Metformin XR", "description": "Dapagliflozin tablets, oral, once daily for 24 weeks plus metfomin XR tablets (up to 2000mg), oral, once daily for 24 weeks"}, {"id": "OG001", "title": "Dapagliflozin 5 mg", "description": "Dapagliflozin tablets, oral, once daily for 24 weeks"}, {"id": "OG002", "title": "Metformin XR", "description": "Metfomin XR tablets (500mg up to 2000mg), oral, once daily for 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "185"}, {"groupId": "OG001", "value": "196"}, {"groupId": "OG002", "value": "195"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "52.4", "spread": "3.581"}, {"groupId": "OG001", "value": "22.5", "spread": "2.741"}, {"groupId": "OG002", "value": "34.6", "spread": "3.296"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "pValueComment": "Secondary endpoints were tested following a sequential testing procedure at alpha=0.05. Significance was claimed only if DAPA 5MG + MET is superior to both controls.", "statisticalMethod": "modified logistic regression", "paramType": "Mean Difference (Final Values)", "paramValue": "29.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "20.8", "ciUpperLimit": "39.0", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.633"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0003", "pValueComment": "Secondary endpoints were tested following a sequential testing procedure at alpha=0.05. Significance was claimed only if DAPA 5MG + MET is superior to both controls.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "17.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "8.1", "ciUpperLimit": "27.4", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.947"}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) in Subjects With Baseline HbA1c \u2265 9% at Week 24 (Last Observation Carried Forward [LOCF])", "description": "HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 4, 8, 12, 16, 20, and 24 in the double-blind period.", "populationDescription": "All randomized participants who received study medication and had nonmissing values at baseline and Week 24 (LOCF) in subjects with baseline HbA1c \u2265 9%", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "% of hemoglobin", "timeFrame": "From Baseline to Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin 5 mg + Metformin XR", "description": "Dapagliflozin tablets, oral, once daily for 24 weeks plus metfomin XR tablets (up to 2000mg), oral, once daily for 24 weeks"}, {"id": "OG001", "title": "Dapagliflozin 5 mg", "description": "Dapagliflozin tablets, oral, once daily for 24 weeks"}, {"id": "OG002", "title": "Metformin XR", "description": "Metfomin XR tablets (500mg up to 2000mg), oral, once daily for 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "96"}, {"groupId": "OG002", "value": "101"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.01", "spread": "0.1381"}, {"groupId": "OG001", "value": "-1.67", "spread": "0.1361"}, {"groupId": "OG002", "value": "-1.82", "spread": "0.1320"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "pValueComment": "Secondary endpoints were tested following a sequential testing procedure at alpha=0.05. Significance was claimed only if DAPA 5MG + MET is superior to both controls.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.34", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.72", "ciUpperLimit": "-0.96", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1938"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "pValueComment": "Secondary endpoints were tested following a sequential testing procedure at alpha=0.05. Significance was claimed only if DAPA 5MG + MET is superior to both controls.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.57", "ciUpperLimit": "-0.82", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1912"}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in Total Body Weight (kg) at Week 24 (Last Observation Carried Forward [LOCF])", "description": "Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Adjusted mean change from baseline in total body weight at Week 24 (or the last postbaseline measurement prior to Week 24 if no Week 24 assessment was available was determined. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of the double-blind period.", "populationDescription": "All randomized participants who received study medication and had nonmissing values at baseline and Week 24 (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kg", "timeFrame": "From Baseline to Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin 5 mg + Metformin XR", "description": "Dapagliflozin tablets, oral, once daily for 24 weeks plus metfomin XR tablets (up to 2000mg), oral, once daily for 24 weeks"}, {"id": "OG001", "title": "Dapagliflozin 5 mg", "description": "Dapagliflozin tablets, oral, once daily for 24 weeks"}, {"id": "OG002", "title": "Metformin XR", "description": "Metfomin XR tablets (500mg up to 2000mg), oral, once daily for 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "192"}, {"groupId": "OG001", "value": "203"}, {"groupId": "OG002", "value": "200"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.66", "spread": "0.2428"}, {"groupId": "OG001", "value": "-2.61", "spread": "0.2361"}, {"groupId": "OG002", "value": "-1.29", "spread": "0.2378"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.8769", "pValueComment": "Secondary endpoints were tested following a sequential testing procedure at alpha=0.05. Significance was claimed only if DAPA 5MG + MET is superior to both controls.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.05", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.72", "ciUpperLimit": "0.61", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.3388"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "pValueComment": "Secondary endpoints were tested following a sequential testing procedure at alpha=0.05. Significance was claimed only if DAPA 5MG + MET is superior to both controls.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.37", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.04", "ciUpperLimit": "-0.71", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.3399"}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in Total Body Weight (kg) in Subjects With Baseline Body Mass Index (BMI) \u2265 27 kg/m^2 at Week 24 (Last Observation Carried Forward [LOCF])", "description": "Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Adjusted mean change from baseline in total body weight at Week 24 (or the last postbaseline measurement prior to Week 24 if no Week 24 assessment was available was determined. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of the double-blind period.", "populationDescription": "All randomized participants who received study medication and had nonmissing values at baseline and Week 24 (LOCF) in subjects with BMI \u2265 27 kg/m2", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kg", "timeFrame": "From Baseline to Week 24", "groups": [{"id": "OG000", "title": "Dapagliflozin 5 mg + Metformin XR", "description": "Dapagliflozin tablets, oral, once daily for 24 weeks plus metfomin XR tablets (up to 2000mg), oral, once daily for 24 weeks"}, {"id": "OG001", "title": "Dapagliflozin 5 mg", "description": "Dapagliflozin tablets, oral, once daily for 24 weeks"}, {"id": "OG002", "title": "Metformin XR", "description": "Metfomin XR tablets (500mg up to 2000mg), oral, once daily for 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "156"}, {"groupId": "OG002", "value": "154"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.04", "spread": "0.3031"}, {"groupId": "OG001", "value": "-2.88", "spread": "0.2890"}, {"groupId": "OG002", "value": "-1.47", "spread": "0.2907"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValueComment": "Secondary endpoints were tested following a sequential testing procedure at alpha=0.05. Significance was claimed only if DAPA 5MG + MET is superior to both controls.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.16", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.98", "ciUpperLimit": "0.66", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.4191"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValueComment": "Secondary endpoints were tested following a sequential testing procedure at alpha=0.05. Significance was claimed only if DAPA 5MG + MET is superior to both controls.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.57", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.40", "ciUpperLimit": "-0.74", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.4201"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Onset on or after the first date of double-blind treatment and on or prior to the last day of double-blind treatment 24 weeks plus 4 days for non-serious adverse event; plus 30 days for serious adverse event.", "eventGroups": [{"id": "EG000", "title": "Dapagliflozin 5 mg + Metformin XR", "description": "Dapagliflozin tablets, oral, once daily for 24 weeks plus metfomin XR tablets (up to 2000mg), oral, once daily for 24 weeks", "seriousNumAffected": 6, "seriousNumAtRisk": 194, "otherNumAffected": 48, "otherNumAtRisk": 194}, {"id": "EG001", "title": "Dapagliflozin 5 mg", "description": "Dapagliflozin tablets, oral, once daily for 24 weeks", "seriousNumAffected": 9, "seriousNumAtRisk": 203, "otherNumAffected": 32, "otherNumAtRisk": 203}, {"id": "EG002", "title": "Metformin XR", "description": "Metfomin XR tablets (500mg up to 2000mg), oral, once daily for 24 weeks", "seriousNumAffected": 7, "seriousNumAtRisk": 201, "otherNumAffected": 40, "otherNumAtRisk": 201}], "seriousEvents": [{"term": "PULMONARY TUBERCULOSIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 201}]}, {"term": "HERPES ZOSTER", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 201}]}, {"term": "PNEUMONIA", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 201}]}, {"term": "CELLULITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 201}]}, {"term": "CYSTITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 201}]}, {"term": "GANGRENE", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 201}]}, {"term": "PYELONEPHRITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 201}]}, {"term": "OESOPHAGITIS", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 201}]}, {"term": "GASTROINTESTINAL OBSTRUCTION", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 201}]}, {"term": "GUN SHOT WOUND", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 201}]}, {"term": "UPPER LIMB FRACTURE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 201}]}, {"term": "ACUTE MYOCARDIAL INFARCTION", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 201}]}, {"term": "ANGINA UNSTABLE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 201}]}, {"term": "CARDIOPULMONARY FAILURE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 201}]}, {"term": "MYOCARDIAL INFARCTION", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 201}]}, {"term": "DIABETES MELLITUS", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 201}]}, {"term": "BREAST CANCER", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 201}]}, {"term": "CEREBROVASCULAR ACCIDENT", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 201}]}, {"term": "ISCHAEMIC NEUROPATHY", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 201}]}, {"term": "HYPERTENSIVE CRISIS", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 201}]}], "otherEvents": [{"term": "DIARRHOEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 20, "numAffected": 15, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 9, "numAffected": 8, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 21, "numAffected": 14, "numAtRisk": 201}]}, {"term": "NAUSEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 20, "numAffected": 11, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 14, "numAffected": 8, "numAtRisk": 201}]}, {"term": "UPPER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 10, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 11, "numAffected": 10, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 11, "numAffected": 11, "numAtRisk": 201}]}, {"term": "URINARY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 10, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 9, "numAffected": 9, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 12, "numAffected": 10, "numAtRisk": 201}]}, {"term": "DYSLIPIDAEMIA", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version: 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 9, "numAtRisk": 194}, {"groupId": "EG001", "numEvents": 13, "numAffected": 11, "numAtRisk": 203}, {"groupId": "EG002", "numEvents": 8, "numAffected": 8, "numAtRisk": 201}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Anna Maria Langkilde", "organization": "AstraZeneca", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["China", "India"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000529054", "term": "Dapagliflozin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M348449", "name": "Dapagliflozin", "asFound": "Body weight", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}